Thalia Therapeutics Plc

Thalia Therapeutics Plc is a biotechnology company developing RNA-based therapeutics and delivery technologies for oncology and cardiovascular disease. The company's proprietary Nuvec delivery system uses amorphous silica nanoparticles with an irregular surface structure designed to trap, protect, and deliver RNA molecules intracellularly. This silica-based platform can be functionalized with proteins, peptides, antibodies, or radionuclides for targeted therapeutic applications. Additionally, Thalia Therapeutics develops LipTide, a lipid and peptide-based delivery system that mimics natural virus mechanisms for efficient cellular RNA delivery. The company maintains a growing pipeline of RNA-based programs focusing on dual-target cardiovascular treatments, including a novel long-duration siRNA program targeting PCSK9 and lipoprotein. Thalia Therapeutics addresses key limitations in existing nucleic acid delivery systems, offering potential applications across gene therapy, cancer therapeutics, and vaccine development. The company operates as a pre-clinical stage specialist pharmaceutical enterprise, making its technologies available for licensing to pharmaceutical and biotech partners.